StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCCFree Report) in a research report report published on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Roth Mkm lowered their price objective on Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a buy rating for the company in a research report on Friday, May 3rd.

Read Our Latest Stock Analysis on CYCC

Cyclacel Pharmaceuticals Price Performance

CYCC stock opened at $2.18 on Friday. The business has a 50 day simple moving average of $2.13 and a 200-day simple moving average of $3.02. The firm has a market capitalization of $3.18 million, a PE ratio of -0.10 and a beta of 0.54. Cyclacel Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $13.20.

Cyclacel Pharmaceuticals (NASDAQ:CYCCGet Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($2.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.93) by $2.66. The business had revenue of $0.03 million during the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 1,009.04% and a negative net margin of 4,401.34%. During the same quarter last year, the company earned ($7.05) earnings per share. On average, equities research analysts expect that Cyclacel Pharmaceuticals will post -6.32 EPS for the current year.

About Cyclacel Pharmaceuticals

(Get Free Report)

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.

Featured Articles

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.